Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Umbricht

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 6, 2015
Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertinDiana Rofail, Antoine Regnault, Stéphanie le Scouiller, et al.
Biological Psychiatry|June 20, 2003
How specific are deficits in mismatch negativity generation to schizophrenia?Daniel Umbricht, René Koller, Liselotte Schmid, et al.
Schizophrenia Research|July 26, 2011
Ultra high-risk state for psychosis and non-transition: a systematic reviewAndor E Simon, Eva Velthorst, Dorien H Nieman, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 24, 2002
Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophreniaDaniel Umbricht, Franz X Vollenweider, Liselotte Schmid, et al.
Brain Research|August 13, 2004
Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humansDaniel Umbricht, Dimitri Vyssotky, Alexander Latanov, et al.
Schizophrenia Research|October 3, 2012
Cognitive functioning in at-risk mental states for psychosis and 2-year clinical outcomeAndor E Simon, Miriam Grädel, Katja Cattapan-Ludewig, et al.
Sante Mentale Au Quebec|February 7, 2008
[On the front line: survey on shared responsibility. General practitioners and schizophrenia]Emmanuel Stip, Richard Boyer, Amir Ali Sepehry, et al.
Schizophrenia Bulletin|April 23, 2010
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?Robert W Buchanan, Richard S E Keefe, Daniel Umbricht, et al.
The Journal of Clinical Psychiatry|July 15, 2020
Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive DisorderDaniel Umbricht, Markus Niggli, Patricia Sanwald-Ducray, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 20, 2014
A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophreniaDaniel Umbricht, Richard S E Keefe, Stephen Murray, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 6, 2015
Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertinDiana Rofail, Antoine Regnault, Stéphanie le Scouiller, et al.
Biological Psychiatry|June 20, 2003
How specific are deficits in mismatch negativity generation to schizophrenia?Daniel Umbricht, René Koller, Liselotte Schmid, et al.
Schizophrenia Research|July 26, 2011
Ultra high-risk state for psychosis and non-transition: a systematic reviewAndor E Simon, Eva Velthorst, Dorien H Nieman, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 24, 2002
Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophreniaDaniel Umbricht, Franz X Vollenweider, Liselotte Schmid, et al.
Brain Research|August 13, 2004
Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humansDaniel Umbricht, Dimitri Vyssotky, Alexander Latanov, et al.
Schizophrenia Research|October 3, 2012
Cognitive functioning in at-risk mental states for psychosis and 2-year clinical outcomeAndor E Simon, Miriam Grädel, Katja Cattapan-Ludewig, et al.
Sante Mentale Au Quebec|February 7, 2008
[On the front line: survey on shared responsibility. General practitioners and schizophrenia]Emmanuel Stip, Richard Boyer, Amir Ali Sepehry, et al.
Schizophrenia Bulletin|April 23, 2010
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?Robert W Buchanan, Richard S E Keefe, Daniel Umbricht, et al.
The Journal of Clinical Psychiatry|July 15, 2020
Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive DisorderDaniel Umbricht, Markus Niggli, Patricia Sanwald-Ducray, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 20, 2014
A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophreniaDaniel Umbricht, Richard S E Keefe, Stephen Murray, et al.
Pageof 8